1027597-04-1

Hydroxy Tipelukast-d6 has shown to improve symptoms of fatty liver, lobular inflammation hepatocyte hypertrophy and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).